The Life Science Effect

Steven A. Vinson, PMP
  • 5.0 (4)
  • Careers
  • Updated Daily

Have you ever thought about who the people are behind life-saving breakthroughs? How did they get started in their careers? Why did they choose the Life Sciences? What effect do they hope to cause? These are the questions we explore on The Life Science Effect. Gain insights straight from thought leaders, entrepreneurial game-changers, and business executives leading the Life Sciences. Host Steve Vinson explores what it really takes to be effective in this industry as a leader and innovator with a special focus on what's happening here, in the Heartland. We aim to inspire, equip, and empower the next generation of Life Science experts through purpose-driven conversations. Join us weekly as we talk about what happens behind the science and get to know the people who make it happen

  1. 2h ago

    Global Biopharma Manufacturing: Beyond Tariffs and Toward Resilience

    In this episode, Steve Vinson examines the sustained wave of biopharma manufacturing investment in North America and challenges the idea that tariffs were the primary driver. He explores the deeper forces reshaping the industry, including supply chain resilience, demand for complex biologics, and global uncertainty. The discussion focuses on what is actually being built, why it matters, and what to expect over the next one to three years. Episode Overview Steve Vinson steps back to assess the current state of global biopharma manufacturing, with a practical focus on North America. While tariffs initially dominated headlines, he explains why the continued expansion of facilities points to a broader strategic shift driven by risk management rather than cost optimization. The episode walks through the types of manufacturing capacity being developed—API, biologics, fill-finish, packaging, and CDMOs—and explains how each plays a role in building a more resilient supply chain. Steve also highlights the ongoing impact of COVID-era disruptions, energy volatility, talent constraints, and the growing demand for therapies such as GLP-1s and complex biologics. Looking ahead, he outlines likely scenarios for the next one to three years, emphasizing the importance of execution, including qualification, tech transfer, and operational readiness, as the key differentiators in delivering value from these large-scale investments. Key Takeaways • Manufacturing investments are continuing despite reduced attention on tariffs • COVID-driven supply chain fragility shifted focus from cost optimization to risk management • Fill-finish and packaging are critical bottlenecks, especially for biologics and GLP-1 products • North America is gaining strategic manufacturing capacity due to stability and demand • Execution—qualification, tech transfer, and operational readiness—is now the primary challenge Who Should Listen • Pharmaceutical and biotech executives • Engineers and technical leaders in life sciences manufacturing • Entrepreneurs and service providers supporting pharmaceutical operations Guests & Hosts Steve Vinson, Host, The Life Science Effect Key Topics Covered • North American biopharma manufacturing investment trends • Impact of COVID on supply chain strategy • API, biologics, fill-finish, and packaging capacity development • Role of CDMOs in managing risk • Talent constraints and automation in advanced manufacturing • One- to three-year outlook scenarios for the industry Key Quotes "Tariffs were the headline. Resilience was the strategy." "Manufacturing advantage isn't poured in concrete, it's proven in execution." Chapters 00:00 – Introduction to manufacturing investment trends 01:13 – What is being built across biopharma capacity 05:11 – COVID supply chain lessons and cold chain explanation 10:26 – Global forces and talent constraints 12:26 – One- to three-year industry outlook scenarios 17:50 – Execution as the differentiator Referenced Resources No specific external resources mentioned in this episode. Practical Applications • Evaluate manufacturing strategies through a risk management lens rather than cost alone • Prioritize execution phases such as qualification and tech transfer in project planning • Consider partnerships with CDMOs to manage capital risk and capacity gaps Credits Podcast: The Life Science Effect Host(s): Steve Vinson Guest(s): Not specified in episode Produced by: BPM Associates Music Credits MUSIC used under the Creative Commons Attribution 4.0 International License: Acid Jazz — Kevin MacLeod Acoustic Motivation — Corna Media Call to Action Subscribe to The Life Science Effect, follow BPM Associates, and visit thelifescienceeffect.com and www.bpm-associates.com to stay informed on life sciences manufacturing trends and leadership insights. Full Transcript 00:00:00 You are about to experience the Life Science Effect, Season 2, brought to you by our presenting sponsor, BPM Associates. 00:00:15 Extraordinary people. 00:00:16 Relationships that matter. 00:00:18 Important change for a better world. 00:00:21 The joy of belonging. 00:00:23 Life. 00:00:24 Science. 00:00:25 Leadership. 00:00:32 Welcome back to The Life Science Effect. 00:00:34 I'm Steve Vinson. 00:00:36 Here's the question I keep asking myself lately. 00:00:40 Did all that North American biopharma manufacturing investment really happen because of the tariffs, or was it something deeper? 00:00:50 Because a year ago, tariffs were the headlines. 00:00:53 Today, the headlines about tariffs are quieter. 00:00:56 But the cranes are still up. 00:00:58 The clean rooms are still going in and getting built. 00:01:01 And the money is still being spent. 00:01:04 So in this episode, I want to step back and look at the state of global biopharma manufacturing with a practical focus on North America. 00:01:13 Not from a political angle, but from a manufacturing one. 00:01:18 So I'll talk about what types of capacity are actually being built: API, biological, drug substance, fill-finish, packaging, devices, CDMOs—those are contract development and manufacturing organizations—and why those choices matter. 00:01:35 We'll also unpack what's really driving decisions now: post-COVID supply chain trauma, national security-driven sourcing rules, energy and geopolitical uncertainty, and real demand signals like GLP-1s and complex biologics. 00:01:54 If you're an entrepreneur, engineer, or technical leader in life sciences, this is about how the manufacturing landscape is being reshaped in real time and what that means over the next one to three years. 00:02:09 Stick around. Let's get into it. 00:02:12 I talked a year ago about tariffs and geopolitical uncertainty. We also discussed the wave of large manufacturing site announcements in North America. The question now is whether those projects are still happening. 00:02:40 The answer is yes—they are proceeding. Once companies commit to large manufacturing assets, they tend to follow through. What changes is the pace, not the direction. 00:03:09 Manufacturing investment has proven more durable than R&D or speculative capacity. Once construction begins, inertia makes cancellation unlikely. 00:03:22 Tariffs were the visible trigger, but not the root cause. COVID exposed vulnerabilities: single-source APIs, fragile cold chains, and long qualification cycles. 00:03:40 Cold chain refers to maintaining temperature control throughout a product's lifecycle. If disrupted, product integrity can fail. 00:05:11 Boards have shifted from cost optimization to risk management. Tariffs helped justify decisions, but resilience is the underlying strategy. 00:06:01 There is a focus on selectively reshoring high-risk APIs, not all APIs. 00:08:01 Biologic drug substance investment is growing, with emphasis on flexible multi-product platforms. 00:08:44 Fill-finish is a major bottleneck, driven by biologics and GLP-1 demand. 00:09:11 Packaging and device integration are increasingly treated as strategic capabilities. 00:09:39 CDMOs are being used to manage risk and delay capital investment decisions. 00:10:26 Global factors such as energy stability and talent constraints are influencing site selection. 00:12:26 Looking ahead, the base case is continued progress with extended timelines. 00:12:59 Focus will shift to qualification, tech transfer, and operational readiness. 00:15:00 The next three years are about finishing well, not starting fast. 00:15:50 Downside risks include talent shortages and increased reliance on CDMOs. 00:15:51 Upside scenarios include regulatory clarity, faster ramp-ups, and stronger domestic ecosystems. 00:17:50 The real opportunity lies in execution, not just construction. 00:18:10 Manufacturing advantage is proven in execution. 00:18:24 If you have feedback or topics you'd like covered, reach out. 00:18:42 It's steven.vinson@bpm-associates.com. 00:18:47 Visit thelifescienceeffect.com and subscribe. 00:18:57 Thanks for listening. Stay strong out there.

    19 min

  2. 1d ago

    Why Prescription Drug Pricing Feels Broken: Cost, Complexity, and Trust in the U.S. System

    In this solo episode, Steve Vinson explores the confusing and often frustrating reality of prescription drug pricing in the United States. Through a personal story, he unpacks how the same medication can cost dramatically different amounts depending on how and where it is accessed. The episode highlights a deeper issue beyond cost—lack of transparency—and what that means for trust in the healthcare system. Episode Overview This episode starts with a real-world example that many listeners can relate to: discovering that the exact same prescription can vary widely in price across pharmacies, mail-order services, and insurance pathways. What seems like a simple decision turns into a complex system of approvals, coordination, and financial trade-offs. From there, the discussion expands into how the pharmaceutical pricing ecosystem actually works. Steve explains the roles of manufacturers, insurance companies, pharmacies, and pharmacy benefit managers (PBMs), and how layered negotiations and rebates contribute to pricing inconsistency. The episode ultimately explores a central tension in healthcare: balancing innovation and affordability. While pharmaceutical breakthroughs require investment and risk, the system designed to support that innovation has become difficult for patients to navigate, creating frustration and eroding trust. Key Takeaways • The same medication can have significantly different prices depending on pharmacy, insurance, and distribution channel • Prescription drug pricing is driven by a complex network of negotiations, not a single market price • Lack of transparency—not just cost—is a major driver of frustration and distrust • Pharmacy Benefit Managers (PBMs) play a key but often invisible role in pricing and formulary decisions • The system is trying to balance innovation, affordability, and financial incentives—but often fails to clearly connect those goals to what patients pay Who Should Listen • Life sciences and pharmaceutical professionals seeking to understand pricing dynamics • Healthcare leaders and policymakers interested in system-level challenges • Engineers and consultants working within healthcare delivery or supply chain systems Guests & Hosts Steve Vinson, CEO, BPM Associates (Host providing perspective on healthcare system complexity) Key Topics Covered • Real-world patient experience navigating prescription pricing • Variability between retail pharmacy, mail-order, and coupon pricing • The role of PBMs and rebate structures • The tension between funding innovation and ensuring affordability • Why transparency is critical to rebuilding trust in healthcare systems Key Quotes "If nobody can explain the price, how can anybody trust the system?" "Healthcare is one of the few areas where people are expected to behave like an informed financial operator at the exact moment they're least equipped to do so." Chapters 00:00 – Introduction and personal experience with prescription pricing 00:03 – The complexity and exhaustion of navigating the system 00:04 – Why pricing confusion matters beyond cost 00:06 – Comparing drug pricing to other markets 00:07 – Understanding the healthcare pricing chain and PBMs 00:08 – Rebates, list prices, and unintended incentives 00:09 – Innovation vs. affordability tension 00:12 – Real-world patient behavior and consequences 00:13 – Why fixing the system is so difficult 00:16 – Transparency, trust, and closing thoughts Referenced Resources No specific external resources mentioned in this episode. Practical Applications • Evaluate multiple pricing pathways (retail, mail order, coupons) before filling a prescription • Recognize system complexity when designing or improving healthcare processes and policies Credits Podcast: The Life Science Effect Host(s): Steve Vinson Guest(s): Not specified in episode Produced by: BPM Associates Music Credits MUSIC used under the Creative Commons Attribution 4.0 International License: Acid Jazz — Kevin MacLeod Acoustic Motivation — Corna Media Call to Action Subscribe to The Life Science Effect to stay informed on life sciences, leadership, and industry challenges. Visit thelifescienceeffect.com and www.bpm-associates.com to learn more. Share your experience or feedback by emailing steven.vinson@bpm-associates.com. Full Transcript You are about to experience The Life Science Effect, Season 2, brought to you by our presenting sponsor, BPM Associates. Extraordinary people, relationships that matter, important change for a better world, the joy of belonging, life, science, leadership. Recently, my wife and I ran into something that perfectly captures how strange prescription drug pricing has become, at least in America. So we both take the same medication. I'll leave out the details for privacy. At one point, I noticed on my insurance company's website that I could get my prescription for about 25% less at a different pharmacy. Same medication, same insurance, different pharmacy, different price. So I moved it over. That turned into the usual modern healthcare scavenger hunt—phone calls, websites, getting pharmacies to talk to each other, messaging my doctor, insurance coordination, waiting for approvals, trying not to run out. Then I discovered something even stranger. Through their mail order service, I could get the same medication shipped directly to me for about 10% of the original price. Not 10% less—about 10% of the original price. At that point, I started thinking, what is the real price of this medication? My wife's prescription is still sitting at the highest price at the original pharmacy, even though it's a pain to deal with. It's exhausting to move it. At some point, future me will have more energy to deal with it. We're not talking about some experimental drug. It's generic. The name brand costs several times more. There are coupons that can make it cheaper, sometimes even cheaper than mail order—but only if prescribed a certain way. I started wondering, who is actually paying the difference? The insurance company? The manufacturer? Now here's the part that sticks with me. I'm a reasonably educated person. I run a company. I understand complex systems. I can spend time figuring this out. And even I found it confusing and exhausting. So what happens if someone doesn't have those advantages? What if they're elderly, working multiple jobs, dealing with illness, or navigating language barriers? The deeper I look, the more it seems the real problem isn't just cost—it's opacity. If nobody can explain the price, how can anybody trust the system? We've all heard the stories: $20 one place, $200 another. Coupons cut prices. Insurance sometimes helps, sometimes makes it worse. We've stopped expecting consistency. In other markets, even confusing ones, you can still answer a basic question: what does this cost? But in prescription drugs, the answer depends on how you enter the system. There are manufacturers, insurers, pharmacies, PBMs, employers, and government programs. Each layer negotiates or adjusts the price. PBMs negotiate with manufacturers, determine formularies, and manage rebates. The list price isn't the real price—it's a starting point for negotiation. Sometimes higher list prices lead to larger rebates, which creates counterintuitive incentives. It's not a simple transaction. It's a network of layered negotiations. We could say it's all exploitation, but that's too simple. Pharmaceutical innovation is real. Developing drugs is expensive, risky, and time-consuming. Many fail. The ones that succeed can take decades. That revenue funds research, rewards risk, and sustains innovation. We have treatments today that extend lives and improve quality of life in ways that weren't possible before. There's a real tension between innovation and affordability. Pricing is trying to solve both, while also rewarding investors and participants in the system. The problem isn't the goals—it's that those goals aren't clearly tied to what patients pay. Meanwhile, patients are skipping doses, delaying refills, and making decisions based on cost rather than medical advice. Even insured individuals can feel like managing prescriptions is a second job. Healthcare is one of the few areas where people are expected to behave like informed financial operators at the exact moment they're least equipped to do so. So why hasn't this been fixed? Because there isn't one system—there are multiple interacting systems with different incentives. Fixing one area often creates pressure elsewhere. Lowering prices might reduce funding for research. Transparency could disrupt negotiated discounts. Simplifying one layer might shift complexity elsewhere. What we have today is a system built over time, layering solutions on top of each other until it became something no one fully designed or controls. When systems become opaque, trust erodes. People don't just need affordability—they need clarity. Right now, the system offers outcomes, variability, and negotiation—but not always explanation. And I keep coming back to the same question: if nobody can explain the price, how can anybody trust the system? Thanks for listening. I'd love to hear your experience. Send me an email at steven.vinson@bpm-associates.com. Check out thelifescienceeffect.com, subscribe, and stay strong out there.

    18 min

  3. 1d ago

    Infrastructure as Innovation: How Ossium Health is Redefining Bone Marrow Access

    In this episode, Steve Vinson reflects on a recent Indianapolis Business Journal article about Ossium Health and its approach to bone marrow banking. He explores how innovation in life sciences often comes not from new discoveries, but from improving systems, logistics, and execution. The discussion highlights why infrastructure and operational excellence are becoming critical to the future of medicine—and why Indiana is uniquely positioned to lead. Episode Overview This episode examines Ossium Health's effort to build a scalable bone marrow banking system using donations from deceased organ donors. Rather than relying on the availability of live donors, Ossium is creating a reliable, on-demand infrastructure that can drastically improve patient access to life-saving treatments. Steve focuses on the broader implication: many of today's bottlenecks in healthcare are no longer scientific—they are logistical. He explains how solving access and delivery challenges can unlock the full potential of existing medical science. The conversation also turns to Indiana's role in this evolving landscape. While not traditionally viewed as a biotech hub, the state's strengths in operations, logistics, and disciplined execution make it a key player in the future of advanced therapies and complex medical supply chains. Key Takeaways • Innovation in life sciences is often driven by systems and logistics, not just scientific breakthroughs • Access to treatment—not lack of science—is a major bottleneck in modern medicine • Bone marrow banking from deceased donors could significantly improve patient outcomes • Infrastructure, reliability, and execution are critical enablers of advanced therapies • Indiana's strengths in operations and logistics position it as an emerging life sciences hub Who Should Listen • Life sciences and pharmaceutical professionals • Operations, supply chain, and engineering leaders • Healthcare innovators and biotech investors Guests & Hosts Steve Vinson, Host, BPM Associates Key Topics Covered • Ossium Health's bone marrow banking model • Challenges in donor matching and transplant accessibility • The role of logistics and infrastructure in healthcare innovation • Indiana's growing importance in life sciences operations • The shift from discovery-focused to execution-focused innovation Key Quotes "Innovation doesn't always happen in a lab. Sometimes it happens in a process, in a system." "The science to save people already exists. The bottleneck is access." Chapters 00:00 – Introduction and episode context 01:15 – Overview of Ossium Health and bone marrow challenges 02:30 – Logistics as a breakthrough in healthcare 04:00 – Access vs. discovery in modern medicine 05:00 – Indiana's role in life sciences infrastructure 06:30 – The importance of execution and operational excellence 07:45 – Closing reflections and call to action Referenced Resources Indianapolis Business Journal (April 17 edition) – Article: "Transplant Tech, Ossium Health aims to revolutionize role of Bone Marrow Banks" by Daniel Bradley Practical Applications • Evaluate where operational bottlenecks—not technical gaps—exist in your organization • Invest in systems, infrastructure, and process discipline to drive scalable impact Credits Podcast: The Life Science Effect Host(s): Steve Vinson Guest(s): Not specified in episode Produced by: BPM Associates Music Credits MUSIC used under the Creative Commons Attribution 4.0 International License: Acid Jazz — Kevin MacLeod Acoustic Motivation — Corna Media Call to Action Subscribe to The Life Science Effect and follow BPM Associates for more insights on leadership, operations, and innovation in life sciences. Visit thelifescienceeffect.com and www.bpm-associates.com to stay connected and explore more content. Full Transcript Speaker: You are about to experience The Life Science Effect, Season 2, brought to you by our presenting sponsor, BPM Associates. Extraordinary people, relationships that matter, important change for a better world, the joy of belonging, life, science, leadership. Recently, I read an article in the Indianapolis Business Journal about a company called Ossium Health. I haven't really been able to stop thinking about it, not because it was flashy or because it promised some futuristic miracle, but because it showed how progress can often really happen through systems, logistics, and people doing disciplined work behind the scenes. And maybe most importantly, because it's happening right here in central Indiana. So today I want to share my reaction to that article, talk about why it caught my attention, and suggest a few things it might mean for the future of life sciences in our state. The article starts with a patient who needs a bone marrow transplant. That's already a high-stakes situation. For a lot of diseases like certain cancers and blood disorders, a transplant can be the difference between life and death. And here's the challenge: finding a compatible donor is incredibly difficult. Only about one in four patients has a matching relative, let alone one that's willing to donate bone marrow. Everybody else has to rely on registries, timing, and sometimes luck. So what this company, Ossium Health, is trying to do is change that equation. At its core, Ossium Health is building a bank of bone marrow from deceased organ donors. Instead of waiting for a live donor to be available at the exact moment a patient needs one, they recover bone marrow, process it, freeze it, and store it—sometimes for decades. Then when a physician needs a match, they can request it and receive it quickly, sometimes within a day. Now think about that. This isn't just a medical breakthrough, it's a logistics breakthrough. It's about availability, speed, and reliability. In other words, it's infrastructure. The part that made me pause was the idea that before this approach, bone marrow from organ donors wasn't used systematically—not because it wasn't valuable, but because the systems to recover, preserve, and distribute it at scale didn't exist. In a lot of cases, the opportunity was just lost. That's the moment where innovation happened—not in a lab, not in a new molecule, but in a process, in a system. The article mentions that about 18,500 people each year are diagnosed with conditions where bone marrow transplants are their best treatment option. That's not a niche problem—it's a systemic problem. The science to save people already exists. The bottleneck is access. The company's headquarters are in San Francisco, but their medical operations are here in Indianapolis. They've built a facility with large cryogenic storage systems designed to store bone marrow for years, ready to be shipped when needed. They're growing, raising funding, hiring, and scaling. What stands out most is the location. Indiana may not be Boston or San Francisco, but we know how to build and run systems. We know how to operate at scale, move things reliably, and maintain quality over time. What companies like Ossium are showing is that the future of medicine doesn't just depend on discovery—it depends on execution. If you step back, this fits into a broader pattern: advanced therapies, complex supply chains, and highly regulated environments all require disciplined operations. That's where Indiana continues to show up—not always in headlines, but in infrastructure and capability. The question is: if the future of medicine depends on systems like this, what role will Indiana play? Because the demand for these capabilities will only grow. One of the things I've learned working on complex projects is that progress rarely comes from a single breakthrough. It comes from coordination, planning, and people doing their jobs well day after day. It's not glamorous, but it's essential. And when it's done right, it saves lives. So when I read this article about Ossium Health, I didn't just see a medical story. I saw a systems story, a logistics story, and an Indiana story. Go check out the article. It's from the April 17 edition of the Indianapolis Business Journal: "Transplant Tech, Ossium Health aims to revolutionize role of Bone Marrow Banks" by Daniel Bradley. If you visited Ossium or know more about it, I'd love to hear from you. If you agree that logistics, infrastructure, and execution are the key drivers here, send me an email at steven.vinson@bpm-associates.com. You can find us at thelifescienceeffect.com, where you can subscribe and catch us on all podcast platforms. Thank you for listening, and stay strong out there.

    10 min

  4. Feb 24

    AI Validating AI: The Future of Compliance in Life Sciences

    Artificial intelligence is moving fast—but in regulated life science environments, speed without trust is a non‑starter. In this episode of The Life Science Effect, host Steven Vinson reacts to a recent EY article on AI validation in pharmaceutical and biotech settings and explores a fascinating question: Can AI actually be used to validate other AI systems? Steven walks through how regulators are beginning to rethink traditional validation models to accommodate AI's non‑deterministic nature, where the same input can produce different, but still acceptable, outputs. Drawing parallels to earlier industry shifts like electronic records, he explains why clear regulatory frameworks are essential for innovation without compromising patient safety. The conversation dives into EU‑specific regulations such as GMP Annex 11, Annex 22, and the EU AI Act, while contrasting Europe's proactive approach with the more hands‑off posture emerging in the U.S. Along the way, Steven offers practical insight for entrepreneurs, engineers, and investors navigating AI in regulated environments, and why "robots testing robots" might be less science fiction than it sounds.   EY ARTICLE:  GxP and AI tools: Compliance, Validation and Trust in Pharma | EY - Switzerland   MUSIC used under the Creative Commons Attribution 4.0 International License: Acid Jazz-Kevin MacLeod Acoustic Motivation by Corna Media   Key Discussion Points Why AI validation is different from traditional computer system validation What "acceptable ranges of output" mean for regulated AI systems Using AI to validate AI: hype vs. reality Overview of EU regulations: GMP Annex 11, Annex 22, and the EU AI Act Lessons from the transition from paper records to electronic systems Why regulatory clarity enables innovation in pharma and biotech Notable Quotes "AI is a tool—and tools still have to be validated." "With AI, different outputs are okay, as long as they fall within what's acceptable." "I just love the idea of robots testing robots." "ChatGPT does not equal AI." "AI is a fantastic tool, but it's not the solution to every problem." Call to Action If you're working with AI in regulated environments—or thinking about it—subscribe to The Life Science Effect, leave a review, and share this episode with your team. Want to join the conversation? Email steven.vinson@bpm-associates.com or visit thelifescienceeffect.com.   Transcript [00:00:01] You are about to experience The Life Science Effect, Season 2, brought to you by our presenting sponsor, BPM Associates. [00:00:16] Extraordinary people. Relationships that matter. Important change for a better world. The joy of belonging. Life, science, leadership. [00:00:29] A few years ago, when we all started learning about ChatGPT and were amazed by it, my first thought was: how can this be used for GMP validation in the pharmaceutical and medical device industries? For testing the equipment that makes products, and the systems used to manage manufacturing and R&D. [00:00:57] I asked a colleague who works in the quality and regulatory space for pharma and medical devices, "What are you hearing? What are you seeing?" He said, "AI is a tool, and you have to validate the tools you use for testing." [00:01:15] That led to a bigger question. He had asked someone from the FDA at a conference: how do you validate an AI when most of us—even the people who design AI—aren't 100% sure what's going on inside it? [00:01:31] Fast forward a few years. I've been reading articles and digging into this topic, and I came across a really interesting piece—more like a blog post—on EY's website. I'll link to it in the show notes. [00:01:47] It's written by Martin Blank, a partner at EY in Switzerland, focused on life science regulatory work. EY is one of the large global consulting firms, similar to Accenture. Because of his background, the article has more of an EU perspective, but much of it applies to the U.S. as well—though the U.S. may be a bit behind. [00:02:09] The article is titled "AI Validation in Pharma: Maintaining Compliance and Trust." It caught my attention for a few reasons. I was actively looking for examples of how AI is being used, and I wanted something relatively recent. This was published in October 2025, and I'm recording this in early 2026, so it felt timely. [00:02:32] What really grabbed me was that he talks about using AI to validate AI. [00:02:46] It's kind of like robot-on-robot violence. [00:02:50] I, for one, welcome our robot overlords. [00:02:58] I read the article and thought I'd share my reactions with you. The big takeaway right away is that AI can absolutely be validated. That answers the question from a few years ago. The real question is: how? [00:03:25] In traditional computer system validation, you provide a specific input and expect a specific output that matches exactly. With AI, you might give the same input multiple times and get different outputs. [00:03:48] Regulators are saying that's acceptable—as long as you expect a range of outputs and all of them fall within what's acceptable for the intended use. [00:04:03] For example, if you ask a chatbot whether there are interactions between ibuprofen and a GLP‑1 drug, you'd expect some variation in how the answer is presented. But every answer should reflect the real interactions. It shouldn't hallucinate or invent risks that don't exist. [00:04:39] The same principle applies whether AI is supporting research, identifying drug candidates, or helping design a testing strategy for a drug or a piece of equipment. [00:04:56] I found that fascinating. And while that wasn't the only focus of the article, it's the part that really excited me. [00:05:06] First, this absolutely can be done if you understand the regulations. Second, I just love the idea of robots testing robots. [00:05:29] So what are the regulations involved? In the EU, there's GMP Annex 11 for computerized systems—traditional systems, what we might think of as pre‑2020 technology. There's also GMP Annex 22, which is specific guidance for AI used in GMP environments. [00:05:55] Then there's the EU AI Act, which governs AI more broadly—not just pharma and medical devices. [00:06:13] The U.S. has been discussing similar approaches, but with recent political changes, it appears the U.S. is choosing to let industry largely govern itself. The EU, on the other hand, has taken a proactive approach and has been rolling out AI regulations in phases since around 2023. [00:06:30] They started with lower‑risk applications and are working toward higher‑risk ones. That may sound backward, but it allows regulators to learn and adapt as complexity increases. [00:06:47] You also still have to comply with GDPR. Even if you're using AI, privacy and personal data protections don't go away. [00:07:10] And of course, GxP standards still apply globally—FDA, EU, Asia‑Pacific, Brazil. There's a fair amount of harmonization across regions, and those expectations exist regardless of what tool you're using. [00:07:20] Is this a big deal? I think it's a very big deal. [00:07:35] I remember in the late 1990s, when electronic records started replacing paper, the industry was asking for a regulatory framework. The rules were written as if everything would stay on paper forever. It took time, but that framework eventually came. [00:08:15] I'm glad the EU is getting out in front of AI. Regulators are focused on patient safety and drug effectiveness. They want more effective therapies, more of them, and they want them to be safe. AI presents a real opportunity to innovate, but it has to be done within a clear regulatory structure. [00:08:44] If the U.S. decides it wants to participate more actively in this future, it can likely build on much of what the EU has already developed. [00:09:04] I know I've been talking a lot about AI lately. I promise there's more going on than just AI. [00:09:18] As someone recently said on a panel discussion, ChatGPT does not equal AI. AI has been around for a long time. What's new is the speed and scale at which it's advancing. [00:09:33] As Raul Zavaleta once told me, AI is just a tool. A fantastic tool—but not the solution to every problem. [00:09:46] So yes, I'm on an AI kick, and it probably won't stop anytime soon. But I will mix in other topics too. [00:10:05] If you're an AI expert or someone doing real work in this space—especially in regulated environments—I'd love to talk. This EY article focused more on how to approach AI, not how people are actually using it. I'd love to hear what problems are being solved and how teams are navigating the regulatory landscape. [00:10:24] If you want to continue the conversation, email me at steven.vinson@bpm-associates.com or visit thelifescienceeffect.com. [00:10:35] You can find us on all the major platforms. Don't forget to subscribe, leave a review, and do all the internet things. [00:10:41] Thanks for listening. Stay strong out there.

    11 min

  5. Jan 30

    How Modular Biotech is Changing Everything - Even in Orbit

    In this episode, host Steve Vinson dives into one of the most futuristic — yet rapidly emerging — trends in life sciences: transportable and point‑of‑care pharmaceutical manufacturing. After discovering a compelling ISPE article, Steve explores how modular clean rooms, distributed manufacturing models, and space‑ready production units are reshaping the future of medicine. From personalized tablet production to on‑demand therapies in extreme environments, these technologies could redefine how and where healthcare happens. Drawing on his 30+ years in manufacturing, Steve connects these innovations to what he's seeing in real project work, including the rise of standardized, copy‑and‑paste biotech facilities. He discusses the biggest challenges ahead — regulatory harmonization, operator training, and safety — and why solving them could open the door to a new era of accessible, hyper‑localized medicine. Whether you're an entrepreneur, biotech professional, investor, or simply curious about the future of therapeutics, this episode offers a fast, engaging look at where the industry is headed — including potential applications as far‑flung as Antarctica… or outer space.            LINK TO iSPEAK BLOG POST Update on Transportable and Point of Care Manufacturing | Pharmaceutical Engineering   MUSIC: Acid Jazz-Kevin MacLeod used under the Creative Commons Attribution 4.0 International License   Detailed Show Notes Main Discussion Points Overview of ISPE article on transportable and point‑of‑care manufacturing Why point‑of‑care production is a potential game‑changer Medicine in space and other extreme‑environment applications Distributed manufacturing and standardized multi‑facility models Regulatory challenges and the push for global harmonization Real‑world examples: CAR‑T modular clean rooms, PrivMed tablets, BioNTainers How this relates to Steve's experience in biotech projects What questions remain — and why this could be transformative by 2030   Key Quotes "Imagine being on the moon and still getting antibiotics without waiting for Earth to deliver them." "Distributed manufacturing could allow pharma to scale faster and more consistently than ever before." "These challenges are big — but they're solvable, and that's what excites me." "Point‑of‑care production moves medicine to wherever the patient is — even Antarctica or space." "By 2030, this could be a full‑blown wave reshaping the entire industry."   Call to Action Enjoyed this episode? Subscribe, leave a review, and share it with a colleague who follows biotech innovation. For links, resources, and all platforms, visit thelifescienceeffect.com. Want to continue the conversation? Email Steve at steven.vinson@bpm-associates.com.   TRANSCRIPT 00:00:00 You're about to experience The Life Science Effect, Season 2, brought to you by our presenting sponsor, BPM Associates. Extraordinary people. Relationships that matter. Important change for a better world. The joy of belonging. Life. Science. Leadership. 00:00:32 Hello and welcome to another episode of The Life Science Effect. I'm Steve Vinson. Let's get into it. 00:00:37 I was browsing the ISPE website looking for an article or blog post to read — that's at ispe.org, and I'll add the link in the show notes. I knew I'd find something good. There were pieces like "Paper to Pixels: Why Pharma Needs to Digitize," "Discover the Future of Sterile Manufacturing," and "Top Five Future Trends in the Pharmaceutical Industry." 00:01:08 Then I saw Update on Transportable and Point‑of‑Care Manufacturing and stopped in my tracks. I had to read it and react to it here. 00:01:20 If that title doesn't jump out at you, I get it. But after 30 years in manufacturing, anything about transportable or point‑of‑care manufacturing is fascinating. This is true science‑fiction‑meets‑reality territory. 00:01:47 The article, authored by Celeste Frankenfield Lam, PhD, and Wendy McGee, summarizes a presentation Dr. Lam gave at the 2025 ISPE Annual Meeting in October. And it is genuinely fascinating. 00:02:21 Here's what hooked me: point‑of‑care manufacturing — medicine produced where the patient is. That could be your doctor's office. Antarctica. Or space. Yes, medicine in space. 00:02:45 Imagine being on the moon and still getting antibiotics without waiting for a resupply from Earth. Manufactured on site. That grabbed me immediately. 00:02:56 But it's more than medicine in space. The article covers distributed manufacturing — standardized processes across multiple identical sites — and point‑of‑care systems that enable personalized dosing. Imagine a doctor saying, "You need 5 mg, while most people need 4," then pressing a button and producing it on the spot. 00:03:32 Transportable manufacturing means modular, movable manufacturing units — shipped by truck, plane, or even into remote or extreme environments… like space. 00:03:48 The challenges? The technology is incredibly advanced. Operators must run these systems consistently to ensure accurate, safe medicine with no contamination. 00:04:21 These environments are highly regulated. The FDA governs the U.S., the EMA oversees Europe, and every country has its own agency. If something is compliant in the U.S. but you ship it to Brazil, their regulations differ. Harmonizing regulatory frameworks across countries is a major challenge — but smart people are working on it. 00:04:40 The goal: one harmonized regulatory standard so manufacturing units can operate safely anywhere — even in orbit. All aimed at producing safe, effective medicine so Steve can get healthcare in space. 00:05:42 My reaction? I'm hooked. I'll be following every new development. The article gives examples of companies working on these technologies, and you can click through — it's free; you don't need to be an ISPE member. 00:06:02 I've been part of ISPE before, and I'm getting involved again. It's a fantastic organization. 00:06:18 Is this a big deal? Yes. Potentially huge. 00:06:24 At BPM Associates, we work with clients using distributed models — multiple facilities built exactly the same to maximize consistency and flexibility. If you were blindfolded and moved from one to another, you wouldn't know where you were. 00:07:11 I've seen this approach for years, especially in microchip manufacturing in the '90s — duplicate the factory exactly, innovate later. This is becoming true in pharma. 00:07:51 Now, seeing point‑of‑care machines and modular systems emerging is incredibly exciting. 00:08:03 I want to read more about the biggest challenges. Training, competency, and regulatory compliance seem solvable. But are there challenges that aren't solvable? That's what I want to learn. 00:08:30 By 2030, this could be the next big wave. 00:08:34 If you work in this space — the companies mentioned include a CAR‑T modular clean‑room company, PrivMed's point‑of‑care tablet production technology, and BioNTech's BioNTainers for modular mRNA vaccine production — email me. 00:09:41 steven.vinson@bpm-associates.com 00:09:47 No script today — just vibes. Links in the show notes. If you liked this episode, share it with a friend. Subscribe on your favorite platform. Visit thelifescienceeffect.com for all podcast links. And send me an email — I'd love to talk more. 00:10:08 Thanks for listening. Stay strong out there.

    10 min

  6. 12/08/2025

    Global Biotech - Is America Falling Behind?

    In this episode, Steve Vinson dives into a provocative article by US Senator Todd Young, exploring the shifting landscape of global biotech innovation. With China's rapid advances—highlighted by a breakthrough lung cancer drug—Steve analyzes the factors behind America's waning leadership, from fragmented policy and regulatory uncertainty to funding challenges and talent migration. Drawing on his own industry experience, Steve discusses the impact of immigration crackdowns, supply chain vulnerabilities, and the long-term effects of reshoring manufacturing. Listeners will gain insight into the political and economic forces shaping biotech's future, the importance of global collaboration, and the risks of falling behind. Whether you're a new entrepreneur or a technical professional in life sciences, this episode offers actionable perspectives and invites you to join the conversation on how the US can reclaim its edge in biotech innovation.   Link to Senator Youg's article:  https://www.foreignaffairs.com/united-states/how-america-can-win-biotech-race#   MUSIC: Acid Jazz-Kevin MacLeod used under the Creative Commons Attribution 4.0 International License   Detailed Show Notes Main Discussion Points China's biotech innovation and breakthrough lung cancer drug US policy fragmentation and regulatory uncertainty Biotech funding challenges and investor risk Impact of immigration crackdowns on talent Supply chain vulnerabilities and tariffs Reshoring US manufacturing and its costs Lessons from the semiconductor industry Call for audience insights on political and trade issues Key Quotes "China's catching up doesn't bother me—it's not a zero-sum game." "What concerns me more is the US falling behind." "Investors want to predict risk, but uncertainty is driving capital elsewhere." "We don't want a brain drain; we need that talent." "Significant investments are being made, but it will take years for new facilities to come online." Call-to-Action (CTA) Subscribe to The Life Science Effect, leave a review, and share your thoughts at steven.vinson@bpm-associates.com. Visit thelifescienceeffect.com for more episodes and resources.   TRANSCRIPT: You are about to experience the Life Science Effect. Season 2. Brought to you by our presenting sponsor, BPM Associates. Extraordinary people. Relationships that matter. Important change for a better world. The joy of belonging. Life. Science. Leadership. Welcome to the next episode. I just read this piece in Foreign Affairs, and it's called "How America Can Win the Biotech Race." It's by Todd Young, who happens to be a senator from Indiana, United States senator, a Republican from Indiana. It was published on October 15th, so it's relatively recent. Key points that I found and what caught my eye was they're talking about a Chinese biotech company that developed a lung cancer drug that outperformed Merck's best-in-class treatment. And it sort of is a signal of China's rapid innovation. The US seems to be—now remember, this is a United States Senator, a Republican—so a lot of this is, you would have to take it from a political point of view. And so I'm not going to say I agree with everything in this article. I would have to do a little more assessment and research. So when you hear me saying the US is losing ground in biotech because of fragmented policy and regulatory hurdles and stagnant funding, I don't know 100% how much of that is accurate. However, I would say there is fragmented policy. I would agree with that. You've heard me say it on this podcast where there's uncertainty in what the regulatory landscape is going to look like given the new administration. And since I first published those episodes earlier this year, things have not gotten better in those terms. And the funding has dried up for biotech. Some of it's starting to make a comeback, but a lot of the funding dried up because investors expect a return and they expect to be able to predict the return, or at least predict the risk. So there's always risk and they want to be able to predict what that risk is going to look like. With the new administration, a lot of things remain unclear with tariffs, how the FDA is going to approach regulation, how they're going to view certain scientific data. There's uncertainty there. So the investors are looking for somewhere else to put their capital. So China, in the meanwhile, hasn't had a big change like we have. And they've been investing billions of dollars. And they're able to, with their system, they're able to pick winners and like who's likely to be a winner and redirect capital to those things that look most promising. And so how did they hit me? Well, I was a little bit surprised how quickly China's catching up, but only a little because I've known China was making these big investments. And I've known that they've been attracting a lot of talent into the industry. And it is a little bit annoying because the US has historically led in biotech innovation. And it's one of the things we brought to the world, right, in terms of the US having this—it would attract global talent. It would attract global capital. And we had these hubs of innovation. And the capital got really good at predicting risk. And they knew not everything would win, but they knew how to invest in a way that over the long haul they could win. And that really sparked a lot of innovation. Todd Young didn't mention it in this article, but I think one of the problems we have right now is with this immigration crackdown. They've cast this wide net that's—a lot of people are getting wrapped up in it who aren't criminals. They just have had their visas canceled. They've had different things happen. And a lot of students are seeing this and a lot of scientists are seeing this. So if you're from another country, and I was curious why—well, I think I know why, but it would be interesting for him to at least address that and say, you know, talent may start to slow down because of the immigration crackdown. And I'd love it if he would talk with the administration. He could probably get their ear way easier than a Democrat senator could, right? So Democratic editor and wanted to talk to you. Administration, they probably couldn't even get in the door, but Todd Young could, and say, hey, and maybe he is behind the scenes. I don't know, maybe politically he couldn't put it out there in an article that he's saying, hey, maybe we need to back off the academic immigrants, you know, because we need that talent. We don't want a brain drain. So who knows what goes on behind closed doors. Does it feel like a big deal or is it just noise? Well, I think of that a couple of ways. One is China's catching up doesn't bother me that much, because I don't see it as a zero-sum game. I see it as, hey, China's China, and they're doing things to develop their biotech industry, which will result in medicines and devices and products that will benefit patients. And China's not going to just keep it in China. Well, first of all, over a billion people in China get—a lot of people get to benefit. That's a lot of human beings whose lives are being improved, even if it was just China. But they're going to export these products and the knowledge, and more and more products are going to be available globally. I think that's good. I would like for the US to continue doing the same thing. And what could be better than China and the US and other countries getting better and better at biotech? So just because China's getting, you know, catching up, it doesn't bother me. What bothers me more is that the US has fallen behind. So it really connects with a lot of the things I've seen because it makes me think about how US companies are increasingly dependent on Chinese firms for research, manufacturing, and things like that. And supply chain vulnerabilities. You know, we've experienced a lot of supply chain vulnerabilities over the past five years or so. And then with the tariffs, if you are getting your active ingredients or intermediates from China for your products made in the US, there's going to be a tariff on those products being sent from China, which increases your costs, which increases the cost to the patient. And we talk a lot about cost to the patient, right? It's a problem. And so you say, well, then won't the tariffs cause companies to build in the US? Billions, tens of billions of dollars are being invested in the US right now to build out factories to provide these things that maybe they used to get from China. So one view is, okay, won't that help the US stop falling behind because we'll have these facilities here. Well, there was a reason that they were exported and that these facilities were—they could do it for less money in some other countries, China, for example. So all of these investments in the US, first of all, it's going to take three to five years to start, you know, two to four years, three to five years for these factories to come online with any sort of capacity. And it's going to be more expensive. It just is. It's more expensive to manufacture in the US, so it's going to drive up costs. All of that wasn't in this article, but it was what makes me think of it. He does mention a trend with semiconductors, like how things are being reshored with semiconductors. For a while there, the US was the leader in semiconductors, and then a similar thing happened, and other countries became—the US fell behind, other countries. And now we had this supply chain vulnerability for semiconductors. During the Biden administration, they did some things that caused that to start to improve. And they are continuing to improve. More semiconductors are being reshored, and that's improving. So I'd like somebody smarter than me to kind of look at this and sort of parse through how much of it is political versus how much of it is, no, this is

    9 min

  7. 10/27/2025

    Pharma 4.0: AI, Validation, and the Future of Life Sciences

    Step into the future of pharmaceutical and medical device innovation with Steve on The Life Science Effect. In this episode, Steve explores the transformative power of Pharma 4.0 and Validation 4.0, drawing insights from two thought-provoking blog posts by Robert Perks of Performance Validation. Discover how digital-first strategies, artificial intelligence, and continuous monitoring are reshaping compliance, quality assurance, and operational efficiency in life sciences. Steve breaks down the shift from paper-based systems to predictive analytics, highlighting the importance of aligning people, processes, and technology in a highly regulated industry. Whether you're a new entrepreneur, engineer, or project manager, you'll gain actionable takeaways on embracing digital transformation, collaborating with regulators, and staying ahead of industry trends. Tune in for key lessons, expert perspectives, and a call to action for leaders ready to drive change in pharma and medical devices. Keywords: Pharma 4.0, Validation 4.0, AI in life sciences, regulatory compliance, digital transformation.   BLOG POSTS MENTIONED: Embracing Pharma 4.0 — A Strategic Imperative for a Digital-First Future  - Performance Validation   The Transformative Impact of Artificial Intelligence on Validation in Life Sciences  - Performance Validation   MUSIC: Acid Jazz-Kevin MacLeod used under the Creative Commons Attribution 4.0 International License   TRANSCRIPT: 00:00:00 HOST: You are about to experience the Life Science Effect, Season 2, brought to you by our presenting sponsor, BPM Associates. 00:00:15 HOST: Extraordinary people. HOST: Relationships that matter. HOST: Important change for a better world. HOST: The joy of belonging. HOST: Life. Science. Leadership. 00:00:29 HOST (Steve): This is Steve, and it's time for another active ingredient. 00:00:33 HOST: I thought for a minute about not calling this segment "active ingredient" today because it's not just one article—it's two blog posts. But it's still off the cuff. I've read these two blog posts and I'm going to interview myself about them. Both are from the website of a great company called Performance Validation. 00:00:54 HOST: Performance Validation is a compliance company. They do validation services, commissioning qualification, building commissioning, temperature mapping, computer system validation—really involved in the nuts and bolts of our industry to ensure processes and equipment run in compliance. 00:01:24 HOST: They're a great company. Check them out at PERFVAL.com. 00:01:32 HOST: The two blog posts are by Robert Perks, Director of Digital Solutions for Performance Validation. I don't know Robert personally, but I really enjoyed these posts. Maybe I'll get to know him someday. 00:01:52 HOST: The first is "Embracing Pharma 4.0: A Strategic Imperative for a Digital First Future." The second is "The Transformative Impact of Artificial Intelligence on Validation in Life Sciences." 00:02:16 HOST: What caught my eye about these articles? If you heard a recent episode where I talked about Industry 4.0, you know I admitted I don't really know what I'm talking about there. So these posts caught my eye—maybe I can learn more about Industry 4.0 if Robert is talking about Pharma 4.0 validation. He even uses the term "Validation 4.0" in the AI article. 00:02:51 HOST: My first reaction was excitement. Pharma 4.0 aligns with Industry 4.0 by connecting resources, information, people, equipment, and software through digital systems. It aligns organizations, processes, and culture with emerging technology. 00:03:24 HOST: Pharma 4.0 is actually a trademarked term by ISPE—the International Society for Pharmaceutical Engineering. They've broadened their scope to include computer systems and medical devices, not just pharmaceuticals. 00:04:13 HOST: ISPE coined Pharma 4.0 to show how Industry 4.0 applies to pharmaceutical manufacturing, development, and distribution. At a high level, it's about aligning resources, systems, organizations, processes, and culture to fit our regulated environment, ensuring quality and compliance while breaking down silos and moving away from paper-based systems. 00:05:13 HOST: Now, we live in a paperless world. How do we align digitally enabled processes to take full advantage? 00:05:31 HOST: Is this a big deal or just noise? It's a big deal. Mr. Perks points out this isn't a future vision—it's happening now. It reminds me of the late 90s when computer systems started replacing paper, and the FDA was asked how they'd regulate digital records. 00:06:32 HOST: Now, there's more collaboration between regulators and industry, leading to optimal solutions. This is the right now, not just the future. 00:06:55 HOST: The second post is "The Transformative Impact of Artificial Intelligence on Validation in Life Sciences." So, what is validation? 00:07:09 HOST: Validation means proof that a medicine, device, or system is fit for its intended use. Proof is evidence—often test results or measurements. 00:08:17 HOST: In pharma and medical devices, validation means proving the system, process, device, or medicine is fit for its intended use—safe, effective, and reliable. 00:08:54 HOST: Historically, validation was retroactive: something happens, a report is written, signed, and filed until an auditor reviews it. If bad product was made, it might already be on the market, leading to recalls and potential harm. 00:09:54 HOST: With Validation 4.0, we're using AI and digital technologies for continuous monitoring and testing. AI can analyze data streams and alert us to issues before bad medicine is made—predictive, not just reactive. 00:10:44 HOST: My company just brought on a new consultant with high-speed manufacturing experience. Life sciences often lag in adopting advanced manufacturing technologies, but Industry 4.0, Pharma 4.0, and now Validation 4.0 are being embraced. 00:11:23 HOST: This is the future—and in some cases, it's today. The next four or five years will be transformative for our industry. I want my company at the forefront, so I'm asking folks to read, listen, try things out, and embrace technology. 00:12:18 HOST: I'd love to hear from others actually working in this space. Someone smarter than me might say it's easier than it looks, or that we could go faster if we removed obstacles. 00:12:39 HOST: Check out these blog posts—I'll link them in the show notes. Let me know what you think. Is Robert Perks onto something? If you have questions or want to see something addressed, let me know. 00:13:00 HOST: As always, you can reach me at stephen.vincent@bpm-associates.com. Visit thelifescienceeffect.com. Find us on all podcast platforms. Like, subscribe, do all the internet things. Most importantly, take care of each other, stay strong, and thanks for listening.

    14 min

  8. 09/15/2025

    The End of Solo Leadership: How Industry 4.0 is Changing the Game

    In this thought-provoking Active Ingredient episode, host Steve Vinson tackles a leadership paradigm that's challenging everything he thought he knew about accountability. Inspired by Sheila Rohra's Forbes article on breaking people silos, Steve dives deep into the tension between traditional "one person accountable" thinking and the emerging concept of shared accountability across teams. Drawing from his real-world experience designing process lane diagrams that keep spanning across departments, Steve explores why Industry 4.0 might be demanding a complete rethink of how we structure organizations. He examines the critical role of trust in making collective accountability work, the importance of baking collaboration into organizational structure rather than just talking about it, and how transparency can prevent destructive turf wars. This episode is particularly relevant for life science leaders navigating the inflection point of the 2020s, where new generations bring fresh approaches to work and innovation. Steve challenges listeners to consider whether traditional accountability models are holding back the collaborative future that patients, healthcare providers, and the industry desperately need. It's a must-listen for anyone ready to question conventional leadership wisdom. Why Breaking People Silos Is The Next Frontier In Leadership MUSIC: Acid Jazz-Kevin MacLeod used under the Creative Commons Attribution 4.0 International License   TRANSCRIPT: HOST (Steve Vinson): [00:00] Testing, testing, one, two. All right, that seems good. This is Steve, and once again, we're going to do an active ingredient where I read an article and interview myself about it. I just read "Why Breaking People Silos is the Next Frontier in Leadership" by Sheila Rohra of the Forbes Councils. This is at Forbes.com - I'll put a link in the show notes. Sheila Arora also happens to be the CEO of Hitachi Vantara. This is not specific to life science today, by the way. I thought I would shake it up a little bit. And if you're leading a life science company or working at a life science company, it'll probably still apply. So I'll let you be the judge of that. [01:30] Why This Article Caught My Eye As a leader at a life science company, I'm always thinking about how we can better design the company, better enhance our culture, just be better. Because I believe that we always want to be improving. And one of the areas I've been thinking a lot about lately is organizational design. This really caught my eye because I want to know what the latest ways of thinking are. And it talked about breaking the silos, which really caught my eye because I'm a big believer in collaboration and working together, and not having people just operate in their own little swim lane. [02:45] My First Reaction - Challenging Traditional Thinking My first reaction is I think I need to do more study because this article is really talking about shared accountability. And one of the things we were taught coming up as young engineers, young professionals, young managers was you cannot have shared accountability. One person needs to be accountable. Now you can have shared responsibility - obviously teams can share responsibility - but one person needs to be accountable. One of the sayings that somebody used to say was "the best way to ensure a dog is going to be hungry is to tell two different people to feed it." Because of course, both of those two people are going to think the other one's going to take care of it. [04:00] Current Challenges with Lane Diagrams The other thing is lanes. When I'm designing a process right now - well, I'm not designing it, I'm on a team that's working on our processes for lead generation and lead conversion and then executing the work that we close - it's a lane diagram because I was trying to go through and say, "Who's accountable for what throughout this?" And it was getting to shared responsibility, shared tasks. So I came up with a lane diagram and now the discussions are, "Well, that's not really one person that does that - it's a conversation that has to happen across lanes." And so I'm making these boxes on my PowerPoint span across lanes and I'm thinking that's defeating the purpose of having the lanes in the first place. This article hits at a particularly appropriate time for me. [05:30] Industry 4.0 and the Bigger Picture The article itself mentions something called Industry 4.0, which I haven't heard of. So I think Industry 4.0 is something I'm going to need to look into because I didn't know there was a 1.0 through 3.0. This is Forbes, so there's probably some latest thinking coming out of business schools about how best to optimize and approach these things. Not that things didn't work well before, but a lot of the things I've learned over the course of my career, maybe it's time for a rethink. In that sense, it's probably a big deal. [06:45] Connection to Current Times We've been talking a lot on this program about risk and uncertainty and how this feels like a moment of change, like an inflection point. We'll look back and say 2020 was a huge inflection point, the years that followed, but then 2024, 2025 - I think we're going to look back and say the 2020s were really a big inflection point. We have newer generations coming along with new ways of living and new ways of approaching work. So it really connects to how are we in the life science industry going to embrace new ways of working, new ways of thinking, new ways of innovating and developing products for patients, new ways of patients interacting with their healthcare providers and new ways of getting those medications prescribed to them, administered to them. We need to be thinking with a forward-looking focus. [08:15] Key Strategies from the Article Now, this article gave a few examples. For one thing, they said trust is absolutely critical because without trust, then it's just going to look like window dressing. So you embrace this collective accountability, this collective responsibility, but you have to have trust that says, "I know everybody's going to be contributing." And I know that the rewards or the recognition is going to be shared and not just given to one person when this was really a shared accountability. There's also the concept of using structure to communicate the message. So this author is recommending that you don't just talk about shared accountability and shared things, but you actually bake it into the structure. And it sends the message that it really is real. [09:30] Our Company's Approach Our goals - I think our company does a good job of this where we're setting goals that reflect shared goals. And we actually use the word "shared" a lot, like shared goals, shared success. So the results of our goals, if we achieve them, we probably have financial success, we have opportunity success. By opportunity success, I mean if you're a project manager or a materials coordinator or some other project support person and you want to get more responsibility or do more cool projects, that is a success that can be shared as our company grows and gets more cool projects. [10:30] Transparency and the Human Factor Using transparency to prevent turf wars is another recommendation this author gives. So I'd like to hear more about that. Like what is it that should be shared, needs to be shared? Do we need to rethink how and what we share in terms of company performance, company profit margins, salary data, things like that? And then finally, the future of work is human. I fully believe the future of work is human with AI and data systems and all the tools that are rapidly coming onto the scene. In order to be successful, as my COO said, it's called copilot, not autopilot. So there's a human factor here and we need to stay on top of that. [11:45] Call to Action If you want to get a hold of me, I'm at Steven.Vinson@BPM-associates.com. Visit our presenting sponsor, BPM Associates at BPM-associates.com. Check out thelifescienceeffect.com. Subscribe, like, comment, shoot me an email. Let's make this a conversation. And above all, stay strong out there.

    10 min
See All (57)

Ratings & Reviews

5
out of 5
4 Ratings

About

Have you ever thought about who the people are behind life-saving breakthroughs? How did they get started in their careers? Why did they choose the Life Sciences? What effect do they hope to cause? These are the questions we explore on The Life Science Effect. Gain insights straight from thought leaders, entrepreneurial game-changers, and business executives leading the Life Sciences. Host Steve Vinson explores what it really takes to be effective in this industry as a leader and innovator with a special focus on what's happening here, in the Heartland. We aim to inspire, equip, and empower the next generation of Life Science experts through purpose-driven conversations. Join us weekly as we talk about what happens behind the science and get to know the people who make it happen

Information